fraz: " PINK on the inside-- I love all WOMEN....".. is this including the ugly ones, and especially the transgender like Caitlyn Jenner ???? LMAO.....
richrd, can you recognize Long_vrts2 if he stands next to you? why do you believe his posts if you don't even know who he is? for the record, he's as clueless as every poster on this MB, he cut and pasted outdated articles published by the back room researchers, or one-sided claims by the CLDX which have not validated by anyone... just like Whip, he starts questioning CLDX management about the insider ownership, and the Rintega's fiasco.. unfortunately, all the CLDX cancer curing drugs work great for rats in the lab, not ready for prime time to treat cancers in human.. CLDX management is very good of creating thunders to raise cash from newly investors, but no rain will be expected for a foreseeable future.. CLDX stock is dream breaker for the next 4 years, their pipeline will be worthless, key execs will get excessive pay raises each year ($5Mil/each), promotions, huge compensations, golden parachutes packages if they get fired, and maintain excessive headcounts that will accomplish nada.. CLDX assets diminished about 90% for the year, and their execs still get huge pay raises, headcounts increased 25% to market with no drug to sell.. how about that eh??
According to the CLDX's resident expert, long_vrts2 has said: "... G-d has blessed me ... with great wealth, much of it from biotech investments ... I may take a little pause when CLDX reaches $100 ..." LMAO
whip is off his medications after a long coma.. still in the suicide watch list with Fraz, J20, Ray, and others... LMAO...
"making up" to the IO's theory is the essential of the insider trading Pyramid scheme designed by CLDX to scam small investors by signalling to the IO's entry/exit price. if this is NOT illegal, then I don't know what is... Do you think SEC would be interested in learning more about this well camouflage scheme??
whip, why do you flip 180 now? no investors should ever trust biotech management, they say one thing but do another... when CLDX posters were raising concerns about the CLDX management, you were muting them by putting them on iggy .. and now, you're saying the same thing.. aren't you show up a day late and a dollar short??
198 headcounts (190x$300K + 8x$3m =$81Mil /yr).. raising $60mil will cover 75% of one year worth of salary, and compensation packages for 198 employees who have been producing nothing for the past 10 years.. Lack of focus to get at least ONE drug to the market, lack of business savvy to protect share holder's values, lack of aggressiveness to deal with the FDA agents, lack of technical know-how to design the best clinical trial to secure the path for the approval, lack of accountability for excessive compensations, hiring, and producing zero result. In short, CLDX management team is a bunch of greedy incompetent. Vote them all OUT..
CLDX presented at the ASCO 2015, and stock price was at the peak.
8users liked this postsusers disliked this posts0Reply
From this AM
by j20tower • May 31, 2015 9:10 AM Flag
HAMPTON, N.J., May 31, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today presented positive results from the Company's randomized, double-blind Phase 2 study of RINTEGA® (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The primary endpoint of the study, progression-free survival at six months (PFS6) was met, and a clear advantage was demonstrated across multiple, clinically important endpoints including overall survival (OS), long-term progression-free survival, objective response rate (ORR) and need for steroids. The data were presented in an oral presentation by David A. Reardon, M.D., Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School; and President of the Society for Neuro-Oncology, as well as the lead investigator of the ReACT study. A webcast/conference call will be held Monday, June 1, 2015 at 8:00 a.m. ET to discuss the results; details are provided below.
RINTEGA is an investigational EGFRvIII specific therapeutic vaccine. Patients with glioblastoma that express the EGFRvIII mutation typically have a worse prognosis than the overall glioblastoma population, including poor long-term survival.
"The results of the ReACT study are striking because we are observing an extremely rare overall survival advantage that is now translating into long-term survival for a number of patients—something not seen in highly aggressive, EGFRvIII-positive glioblastoma," said David A. Reardon, M.D. "Importantly, patients on the RINTEGA arm are not only surviving longer, they are experiencing a notable decrease in the need for steroids and the numerous side effects associated with their use.
the last time I check, CLDX was in business to make money, not a charity organization.. CLDX management needs to focus on accomplishing the ultimate goals that shareholders are expecting.. the final analysis may show that CLDX is full of non-FDA worthless pipeline that management is using to milk all the cash.. this company is over-spent like a drunken sailors...
this is a study (NOT clinical trial) that won't help CLDX to get approval.. this is another way to demolish cash reserved fast.. for paying 198 headcounts (190x$300K + 8x$3m =$81Mil /yr) without any revenues or approved drugs on the market is beyond stupidity.. now CLDX management continues to expand free drugs program ??? this is really #$%$*$%#ked up..
greenunderwood is a mindless foolish pumper.. this new screen name is one of the old paid pumper.. don't listen to this fool..
a scam and a fraud... so far, their drugs are great in treating cancers in rats.. CLDX pays writers to post articles about the effectiveness of their drugs, but none of these claims can be validated by the FDA or statistically verified.. secondary offering at $24.50 is a fraud while scamming investors by looting cash from their huge compensations and excessive hirings while there's no FDA approval or revenue generation in the foreseeable future... VOTE NO to BOOT THEM OUT...
This is on the Celldex website, published in 2012 after the completion of Phase 2.. if it was effective, how come no FDA approval in 2016 ?????? same old #$%$ different year.. more publications but no FDA approval, no revenues, no drug on the market, more compensation for key executives, a lot more employees, but produce NADA. There's a huge disconnect between the FDA approval and bogus claims.. show me the FDA approval, or stop publishing these bogus claims...
Glembatumumab vedotin - Antibody-Drug Conjugate Targeting gpNMB in Metastatic Breast Cancer and Metastatic Melanoma
Glembatumumab vedotin is a fully-human monoclonal antibody-drug conjugate (ADC) that targets glycoprotein NMB (gpNMB). gpNMB is a protein overexpressed by multiple tumor types, including breast cancer and melanoma. gpNMB has been shown to be associated with the ability of the cancer cell to invade and metastasize and to correlate with reduced time to progression and survival in breast cancer. The gpNMB-targeting antibody, CR011, is linked to a potent cytotoxic, monomethyl auristatin E (MMAE), using Seattle Genetics? proprietary technology. Glembatumumab vedotin is designed to be stable in the bloodstream, but to release MMAE upon internalization into gpNMB-expressing tumor cells, resulting in a targeted cell-killing effect.
In late 2012, Celldex completed the Phase 2 EMERGE study in metastatic breast cancer. This exploratory study was prospectively designed to enable the Company to analyze if potential clinical benefit could be linked back to gpNMB expression levels. Final data from the study were presented at the 2012 San Antonio Breast Cancer Symposium and supported a clinical benefit in heavily pre-treated breast cancer patients with tumors that over-express gpNMB, quantified as expression in greater than 25% of tumor
well, the dream team has projected that they will be rich someday because their shares were free 'N clear.. the back up plan is to get the FDA approval to cure cancers for rats.. all their researches and data have shown every drug in the pipeline cured cancers in rats... there're more rats than people in the world.. higher demand and bigger market share to cure cancer for rats than human.. LMAO..
cash value is the support $2.54/share.. it doesn't matter how many posters were presented at the HC, or how many clinical trials are currently conducted.. the only 3 things matters are: 1. FDA approval 2. Drug(s) on the market 3. Revenues/profits and growth ... everything else is #$%$..results matter, not rhetoric that produce nothing.. management are looting cash from this company via their excessive compensations, and keep promising the potential but never produce anything.. time is running out and institutional investors know it....
since revenues rose 160% year/year, CLDX key management get 50% pay raises, and benefit packages increased as well.. how about that eh?? depth pipeline by having two Phase 2 studies across a broad range of indications and multiple Phase 1/2 studies that are actively enrolling patients..
Last but not least, the highlights of the E/R is: CLDX and our collaborators presented seven posters at the recent AACR meeting across multiple compounds in our pipeline .... WoW!!! 7 posters, and you wonder why CLDX stock drops another 5% after the E/R eh!!! LMAO...
nick, if it's market manipulation then you need to put money where your mouth is by buying more to prove your point.. it's kinda funny that market manipulation only when stock drops, but it goes up because of the science .. ACAD drops another 10% today... logic works everytime..LMAO